Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma

Human Gene TherapyVol. 33, No. 17-18 Gene Therapy BriefsNovartis Confirms Deaths of Two Patients Treated with Gene Therapy ZolgensmaAlex PhilippidisAlex Philippidis*Correspondence: E-mail Address: aphilippidis@liebertpub.comMary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA.Search for more papers by this authorPublished Online:16 Sep 2022https://doi.org/10.1089/hum.2022.29216.bfsAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byStrategies for Bottlenecks of rAAV-Mediated Expression in Skeletal and Cardiac Muscle of Duchenne Muscular Dystrophy3 November 2022 | Genes, Vol. 13, No. 11 Volume 33Issue 17-18Sep 2022 InformationCopyright 2022, by Mary Ann Liebert, Inc., publishersTo cite this article:Alex Philippidis.Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma.Human Gene Therapy.Sep 2022.842-844.http://doi.org/10.1089/hum.2022.29216.bfsPublished in Volume: 33 Issue 17-18: September 16, 2022PDF download